Leverage is minimal with total debt of only $3.2M and a debt-to-equity ratio near zero, though the sharp equity rebuild to $3.3B appears tied to the 2025Q4 earnings spike rather than steady operating accumulation and warrants further scrutiny.
Lakefront Biotherapeutics N.V. (LKFT) balance sheet — 22-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 |
|---|
| Total Current Assets | 2.29B | 3.08B | - | - | 4.24B | 4.86B | 5.37B | 5.87B | 1.33B | 1.2B | 1.01B | 374.47M | 213.6M | 173.35M | 132.73M | 65.56M | 109.22M | 84.69M | 59.85M | 80.74M | 79.86M | 36.55M | 12.54M |
| Cash & Short-Term Investments | 2.22B | 3B | - | - | 4.09B | 4.7B | 5.16B | 5.78B | 1.29B | 1.15B | 973.24M | 340.31M | 187.71M | 138.18M | 94.65M | 32.55M | 40.4M | 47.39M | 27.32M | 49.3M | 51.52M | 23.62M | 10.27M |
| Cash Only | 96.26M | 87.87M | - | - | 508.12M | 2.23B | 2.14B | 1.86B | 1.29B | 1.15B | 973.24M | 340.31M | 187.71M | 138.18M | 94.65M | 32.55M | 40.4M | 47.39M | 27.32M | 49.3M | 51.52M | 23.62M | 10.27M |
| Short-Term Investments | 2.12B | 2.91B | - | - | 3.59B | 2.47B | 3.03B | 3.92B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 54.24M | 53.2M | - | - | 77.34M | 128.6M | 173.4M | 80.11M | 33.53M | 41.79M | 23.48M | 16.06M | 13.79M | 31.98M | 33.24M | 28.86M | 63.48M | 31.98M | 26.62M | 22.08M | 24.85M | 9.79M | 2.17M |
| Days Sales Outstanding | 21.44 | 17.46 | - | - | 117.02 | 96.81 | 132.39 | 35.02 | 42.38 | 120.02 | 66.16 | 148.14 | 72.59 | 84.77 | 89.04 | 109.85 | 189.3 | 125.41 | 126.2 | 122.22 | 258 | 317.78 | 101.8 |
| Inventory | 4.95M | 22.49M | - | - | 52.92M | 20.57M | 355K | 255K | 276K | 279K | 300K | 325K | 281K | 249K | 204K | 502K | 1.44M | 1.82M | 3.57M | 4.95M | 3.5M | 3.14M | 98K |
| Days Inventory Outstanding | 94.58 | 276.09 | - | - | 614.72 | 4.61K | 0.25 | 0.22 | 0.31 | 0.47 | 0.78 | 0.91 | 0.92 | 2.2 | 1.55 | 1.47 | 4.52 | 7.79 | 46.98 | 59.87 | 65.38 | 237.49 | 27.77 |
| Other Current Assets | 5.79M | 5.61M | - | - | 12.03M | 9.3M | 33.91M | 4.44M | 4.1M | 3.83M | 10.19M | 17.76M | 11.81M | 820K | 2.51M | 877K | 3.9M | 3.5M | 2.34M | 4.42M | 0 | 0 | 0 |
| Total Non-Current Assets | 1.07B | 327.06M | - | - | 497.5M | 331.31M | 348.38M | 202.68M | 110.64M | 88.63M | 76.11M | 68.04M | 56.86M | 114.03M | 102.6M | 95.49M | 84.74M | 59.02M | 58.98M | 67.98M | 87.78M | 45.02M | 3.07M |
| Property, Plant & Equipment | 76.98M | 80.66M | - | - | 154.25M | 137.51M | 103.38M | 66.05M | 23.14M | 16.69M | 14.96M | 13.78M | 10.09M | 19.52M | 18.1M | 19.52M | 23.89M | 19.29M | 20.29M | 22.91M | 25.96M | 9.4M | 2.63M |
| Fixed Asset Turnover | 15.81x | 13.79x | - | - | 1.56x | 3.53x | 4.62x | 12.64x | 12.48x | 7.61x | 8.66x | 2.87x | 6.87x | 7.05x | 7.53x | 4.91x | 5.12x | 4.83x | 3.79x | 2.88x | 1.35x | 1.20x | 2.96x |
| Goodwill | 0 | 0 | - | - | 69.81M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39.24M | 37.67M | 38.88M | 42.38M | 33.75M | 33.75M | 33.95M | 35.56M | 29.48M | 0 |
| Intangible Assets | 767.03M | 848K | - | - | 146.35M | 60.1M | 67.57M | 24.93M | 3.63M | 2.5M | 1.02M | 1.55M | 2.02M | 7.83M | 9.43M | 10.62M | 13.53M | 3.48M | 4.16M | 6.09M | 17.84M | 4.87M | 447K |
| Long-Term Investments | 523.42M | 46.81M | - | - | 0 | 0 | 8.95M | 11.28M | 6M | 1.75M | 0 | 0 | 0 | 220K | 0 | 1.04M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 3.81M | 198.55M | - | - | 125.72M | 129.66M | 164.01M | 96.22M | 75.36M | 65.7M | 58.17M | 50.98M | 44.46M | 42.65M | 35.7M | 23.27M | 1.28M | 807K | 772K | 4.67M | 7.68M | 1.27M | 0 |
| Total Assets | 3.35B | 3.41B | - | - | 4.73B | 5.19B | 5.72B | 6.07B | 1.44B | 1.29B | 1.08B | 442.51M | 270.47M | 287.37M | 235.33M | 161.06M | 193.96M | 143.71M | 118.82M | 148.72M | 167.65M | 81.56M | 15.61M |
| Asset Turnover | 0.28x | 0.33x | - | - | 0.05x | 0.09x | 0.08x | 0.14x | 0.20x | 0.10x | 0.12x | 0.09x | 0.26x | 0.48x | 0.58x | 0.60x | 0.63x | 0.65x | 0.65x | 0.44x | 0.21x | 0.14x | 0.50x |
| Asset Growth % | -16.87% | - | - | - | -8.83% | -9.17% | -5.78% | 321.58% | 11.91% | 18.73% | 144.81% | 63.61% | -5.88% | 22.12% | 46.12% | -16.97% | 34.97% | 20.94% | -20.1% | -11.29% | 105.54% | 422.4% | - |
| Total Current Liabilities | 49.15M | 152.86M | - | - | 522.54M | 566.47M | 635.27M | 571.79M | 219.91M | 171.7M | 103.79M | 72.41M | 60.36M | 112.56M | 109.01M | 35.36M | 38.22M | 31.34M | 29.75M | 43.36M | 29.28M | 14.06M | 3.61M |
| Accounts Payable | 46.42M | 32.62M | - | - | 133.3M | 134.3M | 171.32M | 142.51M | 68.04M | 47.12M | 31.21M | 29.11M | 29.34M | 29.36M | 22.09M | 18.07M | 22.01M | 15.13M | 13.43M | 13.29M | 25.43M | 9.57M | 2.77M |
| Days Payables Outstanding | 505.25 | 400.41 | - | - | 1.55K | 30.09K | 119.41 | 123.82 | 76.91 | 78.72 | 81.61 | 81.92 | 96.4 | 259.53 | 167.38 | 52.76 | 69.25 | 64.9 | 176.46 | 160.84 | 475.21 | 723.2 | 783.84 |
| Short-Term Debt | 1.29M | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16K | 0 | 0 | 394K | 0 |
| Deferred Revenue (Current) | 97.56K | 32K | - | - | 365.63M | 419.87M | 443.16M | 414.3M | 149.8M | 122.54M | 70.83M | 39.81M | 27.03M | 78.98M | 83.61M | 13.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.12M | 117.5M | - | - | 8.51M | 204K | 12.08M | 6.2M | 1K | 0 | 60K | 368K | 767K | 81K | 177K | 394K | 15.79M | 15.65M | 15.72M | 27.39M | 556K | 0 | 842K |
| Current Ratio | 46.49x | 20.15x | - | - | 8.11x | 8.58x | 8.45x | 10.26x | 6.04x | 6.98x | 9.70x | 5.17x | 3.54x | 1.54x | 1.22x | 1.85x | 2.86x | 2.70x | 2.01x | 1.86x | 2.73x | 2.60x | 3.48x |
| Quick Ratio | 46.39x | 20.00x | - | - | 8.01x | 8.55x | 8.45x | 10.26x | 6.04x | 6.97x | 9.70x | 5.17x | 3.53x | 1.54x | 1.22x | 1.84x | 2.82x | 2.64x | 1.89x | 1.75x | 2.61x | 2.37x | 3.45x |
| Cash Conversion Cycle | -389.24 | -106.86 | - | - | -816.51 | -25.39K | 13.23 | -88.58 | -34.23 | 41.77 | -14.67 | 67.13 | -22.89 | -172.57 | -76.79 | 58.55 | 124.56 | 68.3 | -3.28 | 21.25 | -151.83 | -167.93 | -654.27 |
| Total Non-Current Liabilities | 13.7M | 17.79M | - | - | 1.69B | 1.98B | 2.41B | 2.62B | 5.34M | 102.59M | 220.85M | 5.1M | 3.98M | 7.68M | 7.87M | 7.32M | 7.23M | 3.49M | 4.75M | 6.74M | 28.83M | 6.36M | 1.64M |
| Long-Term Debt | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 16.67M | 5.19M | - | - | 14.69M | 19.66M | 23.04M | 19.56M | 0 | 0 | 9K | 63K | 115K | 167K | 165K | 451K | 867K | 964K | 1.16M | 1.75M | 4.59M | 4.61M | 0 |
| Deferred Tax Liabilities | 0 | 0 | - | - | 20.15M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.19M | 2.62M | 2.4M | 2.69M | 564K | 201K | 292K | 594K | 1.54M | 225K |
| Other Non-Current Liabilities | 11.85M | 12.6M | - | - | 27.35M | 18.83M | 23.09M | 15.25M | 5.34M | 5.24M | 6.05M | 5.04M | 3.86M | 5.32M | 5.08M | 4.46M | 3.67M | 1.96M | 3.39M | 4.7M | 23.64M | 214K | 1.41M |
| Total Liabilities | 62.85M | 170.65M | - | - | 2.21B | 2.55B | 3.05B | 3.19B | 225.25M | 274.29M | 324.64M | 77.52M | 64.33M | 120.24M | 116.88M | 42.68M | 45.45M | 34.83M | 34.5M | 50.1M | 58.1M | 20.43M | 5.25M |
| Total Debt | 3.15M | 6.92M | - | - | 21.9M | 26.86M | 29.44M | 25.38M | 0 | 9K | 63K | 115K | 167K | 393K | 405K | 876K | 1.25M | 1.48M | 1.7M | 4.37M | 7.77M | 7.97M | 0 |
| Net Debt | -93.1M | -80.95M | - | - | -486.22M | -2.21B | -2.11B | -1.84B | -1.29B | -1.15B | -973.18M | -340.2M | -187.54M | -137.78M | -94.24M | -31.68M | -39.15M | -45.91M | -25.61M | -44.93M | -43.75M | -15.65M | -10.27M |
| Debt / Equity | 0.00x | 0.00x | - | - | 0.01x | 0.01x | 0.01x | 0.01x | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.02x | 0.04x | 0.07x | 0.13x | - |
| Debt / EBITDA | 0.01x | 0.01x | - | - | - | - | - | 0.07x | - | - | - | - | - | - | 0.17x | - | 0.10x | 0.17x | - | - | - | - | - |
| Net Debt / EBITDA | -0.19x | -0.15x | - | - | - | - | - | -4.91x | - | - | - | - | - | - | -39.28x | - | -3.09x | -5.33x | - | - | - | - | - |
| Interest Coverage | 4011.63x | 136.71x | -2.39x | 4.18x | -6.74x | -10.54x | -15.42x | 199.92x | -39.28x | -122.40x | -244.47x | -472.97x | -319.01x | -101.78x | -33.35x | -20.34x | 1.38x | 3.37x | -1.80x | -12.43x | -10.82x | -17.02x | -21.02x |
| Total Equity | 3.29B | 3.24B | - | - | 2.53B | 2.64B | 2.67B | 2.88B | 1.21B | 1.01B | 758.7M | 365M | 206.13M | 167.14M | 118.45M | 118.38M | 148.51M | 108.88M | 84.32M | 98.63M | 109.54M | 61.14M | 10.37M |
| Equity Growth % | 57.41% | - | - | - | -4.44% | -1.01% | -7.14% | 136.83% | 19.99% | 33.38% | 107.86% | 77.07% | 23.33% | 41.11% | 0.06% | -20.29% | 36.4% | 29.12% | -14.5% | -9.97% | 79.18% | 489.72% | - |
| Book Value per Share | 50.07 | 49.10 | - | - | 38.45 | 40.36 | 41.04 | 49.91 | 23.30 | 20.45 | 16.60 | 10.22 | 6.85 | 5.81 | 4.46 | 4.48 | 6.12 | 5.03 | 3.98 | 4.77 | 8.09 | 6.84 | 1.75 |
| Total Shareholders' Equity | 3.29B | 3.24B | - | - | 2.53B | 2.64B | 2.67B | 2.88B | 1.21B | 1.01B | 758.7M | 365M | 206.13M | 167.14M | 118.45M | 118.38M | 148.51M | 108.88M | 84.32M | 98.63M | 109.54M | 61.14M | 10.37M |
| Common Stock | 298.91M | 293.94M | - | - | 293.6M | 292.07M | 291.31M | 287.28M | 236.54M | 233.41M | 223.93M | 185.4M | 157.27M | 154.54M | 139.35M | 137.46M | 137.12M | 122.87M | 110.86M | 110.86M | 104.4M | 69.05M | 31.56M |
| Retained Earnings | 243.42M | 210.58M | - | - | -496.69M | -367.2M | -334.7M | -109.22M | -297.78M | -211.44M | -112.27M | -177.32M | -63.94M | -100.11M | -94.77M | -91.14M | -60.08M | -66.87M | -72.49M | -58.96M | -39.03M | -27.73M | -21.19M |
| Treasury Stock | -43.32M | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 5.15M | -5.64M | - | - | -6.45M | -11.9M | -14.1M | -5.98M | -2.29M | -3.01M | -2.09M | -485K | -1.38M | 217K | 994K | 35K | 71.46M | 52.88M | 45.96M | 46.73M | 44.18M | 19.82M | 0 |
| Minority Interest | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying LKFT stock.
As of 2025, Lakefront Biotherapeutics N.V. (LKFT) had total assets of $3.41B including $3.08B in current assets.
Lakefront Biotherapeutics N.V. (LKFT) carries total debt of $6.9M, offset by $3.00B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Lakefront Biotherapeutics N.V. (LKFT) has total shareholders' equity (book value) of $3.24B ($49.10 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Lakefront Biotherapeutics N.V. (LKFT) reported a current ratio of 20.15x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Thin cash against persistent burn
Equity Base Rebuilt Through Reported Gains
According to reported quarterly figures, LKFT's equity rose from $2.4B in 2025Q3 to $3.3B in 2026Q3 while total liabilities fell from $1.1B to $62.9M, indicating a sharp deleveraging that appears tied to the 2025Q4 earnings spike rather than steady operating accumulation.
The shift in equity is driven by retained earnings moving from a deficit of $577.7M to a positive $243.4M, a change that depends heavily on the one-time $782.1M net income in 2025Q4. Because the surrounding quarters show operating losses, the improved balance sheet may reflect a non-recurring event rather than a durable strengthening of the business. Investors should monitor whether retained earnings can stay positive without a repeat of that gain.
Liquidity Ratios Mask Thin Cash Cushion
As reported in financial statements, LKFT's current ratio of 46.49 in 2026Q3 looks exceptionally strong, but cash of $96.3M against quarterly operating cash outflows near $33M to $83M implies a runway that is short relative to burn.
The very high current ratio largely reflects the small liability base after the 2025 restructuring of obligations, not a deep pool of liquid resources. Cash fell from $135.9M in 2026Q2 to $96.3M in 2026Q3 while buybacks continued, which suggests the company is drawing down its cash buffer. This warrants further investigation into how management plans to fund operations without new financing.
Share Repurchases Drawing on Thin Reserves
Based on LKFT's reported figures, the company deployed $38.1M into share repurchases in 2026Q3 while operating cash flow was negative $32.9M, a pattern that may indicate capital returns are funded from balance sheet cash rather than internally generated resources.
Repurchasing stock while operating cash flow is negative runs against the company's reported need to preserve liquidity, and it reduces cash that would otherwise extend the runway. The equity base is also heavily influenced by the non-operating gain in 2025Q4, so per-share value support from buybacks depends on that base being durable. Shareholders should weigh whether these repurchases are a responsible use of constrained resources.
Goodwill Dominates an Asset-Light Base
As reported in the filings, goodwill of $767.0M represents roughly 23% of LKFT's $3.4B total assets in 2026Q3, while net PP&E of $77.0M is small, pointing to an asset base concentrated in intangibles rather than physical capacity.
The large goodwill balance, which rose from $746.0K in 2026Q1 to $767.0M in 2026Q3, indicates a material acquisition or reclassification that the reported data does not explain. Because goodwill is subject to impairment testing, a write-down would hit equity directly and could reverse the retained earnings recovery. Investors should treat the headline asset total with caution given how much of it rests on this single intangible line.
Headline Deleveraging Rests on One Quarter
The strongest challenge to LKFT's balance sheet improvement is that the 2025Q4 net income of $782.1M, which drove the recovery in equity, coincided with $47.5M of operating cash outflow, suggesting the headline strength may not reflect cash generation.
Reported accounting gains can restore equity and shrink liabilities without any corresponding change in cash profile, which is what the figures appear to show. With free cash flow still deeply negative in recent quarters, the apparent balance sheet repair may be an accounting outcome rather than evidence of financial resilience. This distortion warrants close scrutiny before treating the current equity and low debt position as a stable foundation.